HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business (Health)

Set Alert for Business {Health}

HRA Pharma Reveals Big Growth Ambitions In Quest To Become Top-10 OTC Player

A combination of prescription-to-OTC switches, acquisitions and maximising the potential of its existing portfolio will take France’s HRA Pharma to the next level, reveals chief commercial officer Martyn Hilton. 
Health Business Strategies OTC Drugs

Unlock M&A Growth Potential Through Outsourcing

Adopting an effective outsourcing strategy will enable consumer healthcare players to get the most out of their acquisitions, says Baird’s Vincenzo di Nicola.

Business Strategies Health M & A

Crown Labs Spreads Out, GSK Narrows Focus In OTC Skin Care Brand Deal

GSK further narrows consumer health focus with sale to Crown Labs of North American distribution rights for PanOxyl acne wash, Sarna anti-itch lotion, Zeasorb anti-fungal product, Desenex athlete’s foot treatment and Mineral Ice pain-relieving gel. Deals also helps UK pharma pay for its $5.1bn acquisition of oncology drug firm Tesaro.

Health M & A Advertising, Marketing & Sales

Deals

Set Alert for Deals {Health}

Latest From Health & Deals

Crown Labs Spreads Out, GSK Narrows Focus In OTC Skin Care Brand Deal

GSK further narrows consumer health focus with sale to Crown Labs of North American distribution rights for PanOxyl acne wash, Sarna anti-itch lotion, Zeasorb anti-fungal product, Desenex athlete’s foot treatment and Mineral Ice pain-relieving gel. Deals also helps UK pharma pay for its $5.1bn acquisition of oncology drug firm Tesaro.

Commercial Consumer

Coppertone, Dr. Scholl’s On The Block As Bayer Narrows Consumer Health Focus

Bayer will sell Coppertone sunscreen and Dr. Scholl’s foot care brands to focus on growing its core consumer health brands. Although the plan represents ‘failure” in turning around sales for both brands, it is a ‘sensible’ move, say analysts.

Health Wellness

Coppertone, Dr. Scholl’s On The Block As Bayer Narrows Consumer Health Focus

Bayer will sell Coppertone sunscreen and Dr. Scholl’s foot care brands to focus on growing its core consumer health brands. Although the plan represents ‘failure” in turning around sales for both brands, it is a ‘sensible’ move, say analysts.

Commercial M & A
See All

Strategy

Set Alert for Business Strategy {Health}

Latest From Health & Business Strategies

TummyZen Firm Appeals After Heartburn Claims Don't Settle Well In NAD Review

Eli Consumer Healthcare is latest supplement marketer National Advertising Division has advised that tests of separate ingredients do not support claims for a whole product. Following NADs review of TummyZen claims on challenge by Tums firm GlaxoSmithKline, Eli Consumer appeals NAD's recommendations to discontinue claims that its supplement “stops acid production,” is “acid inhibiting,” “halts the secretion of chloride ions in your parietal cells to regulate the release of acid into your stomach,” “supports stomach lining” and is “long lasting."

Wellness Health

Bricks-And-Mortar Pharmacy In The Crosshairs As Zur Rose Aims To Become The Amazon Of European Healthcare

Swiss supply chain disruptor Zur Rose wants to break up the ancient monopoly of European bricks-and-mortar pharmacy and replace it with a tech-driven healthcare offering to rival that of retail giant Amazon, according to a member of the firm’s board, Olaf Heinrich.

Health Business Strategies

Amazon Expands Consumer Health With Advantage Of Cutting Prices

E-commerce giant expands consumer health footprint in past six months with launches of generic OTC drug product lines at prices in some cases significantly undercutting competitors.  Primary Health and SoundHealth OTC drugs range from a few dollars less to about half the cost of brand name equivalents.
Dietary Supplements Commercial
See All

Sales & Earnings

Set Alert for Sales & Earnings {Health}

Latest From Health & Sales & Earnings

Improvement in margin pleases GSK’s Walmsley

GlaxoSmithKline (GSK) is making “very good progress” on improving margins at its Consumer Healthcare business, according to chief executive officer Emma Walmsley.

Health OTC Drugs

Supply issues troubling Bayer Consumer Health

Bayer reported some encouraging third-quarter developments at its Consumer Health business, including the return to shelves of a key OTC brand in China. But there is still more to be done to complete the unit’s turnaround, says global Consumer Health head Heiko Schipper.

Health OTC Drugs

RB enjoys OTC growth ‘ahead of the market’

Reckitt Benckiser’s (RB’s) OTC business performed “materially ahead of the market” in the third-quarter of 2018, chief executive Rakesh Kapoor informed analysts on the firm’s earnings call.

Health OTC Drugs
See All

Litigation

Set Alert for Legal Issues {Health}

Latest From Health & Legal Issues

Keystone Labs Court-Ordered To Halt OTC Drug Manufacturing; Cosmetics Not Affected, It Says

Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.

Legal Issues Manufacturing

OTC-Only PEG Market Nears After Court Passes On Stopping Rx ANDA Withdrawals

US circuit court rejects petitions from Breckenridge Pharmaceutical, Lannett Co., Nexgen Pharma and Paddock Labs to order FDA to conduct a hearing on their requests to sustain approvals for Rx PEG 3350 generics. FDA's approvals of the Rx ANDAs are set to expire Nov. 2; the agency said the Rx products were rendered unapproved in 2006 when the same formulation became available OTC.

Gastrointestinal Health

Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount

Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.

Legal Issues M & A
See All
UsernamePublicRestriction

Register